Adapting Cancer Immunotherapy Models for the Real World

Trends in Immunology

Volumn 37, Issue 6, 2016, Pages 354-363

  Klevorn, Lauryn E ^a   Teague, Ryan M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MO   (United States)

Author keywords

Age; Cancer; Checkpoint blockade; Immunotherapy; Microbiota; Obesity

Indexed keywords

HOST FACTOR; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

AGE; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MICROFLORA; MOUSE MODEL; NONHUMAN; OBESITY; REVIEW; SENESCENCE; TUMOR IMMUNITY; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASMS; PRECLINICAL STUDY; PROCEDURES; TREATMENT OUTCOME;

AGE FACTORS; ANIMALS; ANTIBODIES, MONOCLONAL; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; TREATMENT OUTCOME;

EID: 84963811513     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.03.010     Document Type: Review

References (86)

1. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
2. Larkin J., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 2015, 373:23-34.
3. Postow M.A., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015, 372:2006-2017.
4. Robert C., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015, 372:2521-2532.
5. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
6. Gangadhar T.C., Vonderheide R.H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 2014, 11:91-99.
7. Ogden C.L., et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014, 311:806-814.
8. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156:20-44.
9. Iida N., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013, 342:967-970.
10. Viaud S., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013, 342:971-976.
11. Garrett W.S. Cancer and the microbiota. Science 2015, 348:80-86.
12. Bouchlaka M.N., et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 2013, 210:2223-2237.
13. James B.R., et al. Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth. J. Immunol. 2012, 189:1311-1321.
14. Mirsoian A., et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 2014, 211:2373-2383.
15. Sivan A., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015, 350:1084-1089.
16. Vetizou M., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015, 350:1079-1084.
17. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
18. Wang X., et al. Characterizing exposure-response (E-R) relationship of safety for nivolumab in combination with ipilimumab in patients with previously untreated advanced melanoma. In American Conference on Pharmacometrics (ACoP6) 2015.
19. Pfister G., et al. Naive T cells in the elderly: are they still there?. Ann. N. Y. Acad. Sci. 2006, 1067:152-157.
20. Youm Y.H., et al. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proc. Natl. Acad. Sci. U.SA. 2016, 113:1026-1031.
21. Nikolich-Zugich J. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J. Immunol. 2014, 193:2622-2629.
22. Lazuardi L., et al. Age-related loss of naive T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology 2005, 114:37-43.
23. Chawla A., et al. Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 2011, 11:738-749.
24. Weisberg S.P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
25. Hurez V., et al. Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res. 2012, 72:2089-2099.
26. + T cell-mediated antitumor immunity with aging. J. Immunol. 2004, 173:835-844.
27. Brien J.D., et al. Key role of T cell defects in age-related vulnerability to West Nile virus. J. Exp. Med. 2009, 206:2735-2745.
28. + recent thymic emigrants from aged mice. J. Immunol. 2007, 178:1321-1331.
29. Flood P.M., et al. Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity. J. Immunother. 1998, 21:307-316.
30. Provinciali M., et al. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Gene Ther. 2000, 7:624-632.
31. Yuan R., et al. Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell 2009, 8:277-287.
32. Tsukamoto H., et al. Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18333-18338.
33. Hirokawa K., Makinodan T. Thymic involution: effect on T cell differentiation. J. Immunol. 1975, 114:1659-1664.
34. Toh B.H., et al. Depression of cell-mediated immunity in old age and the immunopathic diseases, lupus erythematosus, chronic hepatitis and rheumatoid arthritis. Clin. Exp. Immunol. 1973, 14:193-202.
35. Singh M., Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat. Biotechnol. 2012, 30:648-657.
36. DuPage M., Jacks T. Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Curr. Opin. Immunol. 2013, 25:192-199.
37. Stromnes I.M., et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 2014, 63:1769-1781.
38. Ono T., et al. Endogenous virus genomes become hypomethylated tissue-specifically during aging process of C57BL mice. Mech. Ageing Dev. 1989, 50:27-36.
39. Chiappinelli K.B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015, 162:974-986.
40. Chuong E.B., et al. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science 2016, 351:1083-1087.
41. Chiappinelli K.B., et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016, 76:1683-1689.
42. Feuerer M., et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med. 2009, 15:930-939.
43. Macia L., et al. Impairment of dendritic cell functionality and steady-state number in obese mice. J. Immunol. 2006, 177:5997-6006.
44. Milner J.J., et al. Diet-induced obese mice exhibit altered heterologous immunity during a secondary 2009 pandemic H1N1 infection. J. Immunol. 2013, 191:2474-2485.
45. Flores K.G., et al. Analysis of the human thymic perivascular space during aging. J. Clin. Invest. 1999, 104:1031-1039.
46. Yang H., et al. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J. Immunol. 2009, 183:3040-3052.
47. Yang H., et al. Obesity accelerates thymic aging. Blood 2009, 114:3803-3812.
48. Salans L.B., et al. Experimental obesity in man: cellular character of the adipose tissue. J. Clin. Invest. 1971, 50:1005-1011.
49. Halberg N., et al. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol. Cell. Biol. 2009, 29:4467-4483.
50. + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med. 2009, 15:914-920.
51. Winer D.A., et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat. Med. 2011, 17:610-617.
52. Weisberg S.P.R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
53. Khan S.H., et al. Diet-induced obesity does not impact the generation and maintenance of primary memory CD8 T cells. J. Immunol. 2014, 193:5873-5882.
54. O'Rourke R.W., et al. Alterations in T-cell subset frequency in peripheral blood in obesity. Obes. Surg. 2005, 15:1463-1468.
55. Young K.M., et al. Is obesity a risk factor for vaccine non-responsiveness?. PLoS ONE 2013, 8:e82779.
56. Calle E.E., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348:1625-1638.
57. Renehan A.G., et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
58. Lu Y.P., et al. Surgical removal of the parametrial fat pads stimulates apoptosis and inhibits UVB-induced carcinogenesis in mice fed a high-fat diet. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:9065-9070.
59. Schneider H.J., et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J. Clin. Endocrinol. Metab. 2010, 95:1777-1785.
60. Zhang Y., et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425-432.
61. Pelleymounter M.A., et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995, 269:540-543.
62. Fenton J.I., et al. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes. Metab. 2009, 11:343-354.
63. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
64. Pollock N.K., et al. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J. Nutr. 2012, 142:251-257.
65. Griffett K., et al. The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis. Mol. Metab. 2015, 4:353-357.
66. Gosalbes M.J., et al. Meconium microbiota types dominated by lactic acid or enteric bacteria are differentially associated with maternal eczema and respiratory problems in infants. Clin. Exp. Allergy 2013, 43:198-211.
67. Madan J.C., et al. Gut microbial colonisation in premature neonates predicts neonatal sepsis. Arch. Dis. Child. Fetal Neonatal. Ed. 2012, 97:F456-F462.
68. Mshvildadze M., et al. Intestinal microbial ecology in premature infants assessed with non-culture-based techniques. J. Pediatr. 2010, 156:20-25.
69. Dominguez-Bello M.G., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11971-11975.
70. Kabat A.M., et al. Modulation of immune development and function by intestinal microbiota. Trends Immunol. 2014, 35:507-517.
71. + T cells via TLR4 signaling. J. Clin. Invest. 2007, 117:2197-2204.
72. Grivennikov S.I., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
73. Wallace B.D., et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010, 330:831-835.
74. Boleij A., et al. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin. Infect. Dis. 2015, 60:208-215.
75. Toprak N.U., et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin. Microbiol. Infect. 2006, 12:782-786.
76. + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:12204-12209.
77. + T cells and Treg function. Gut Microbes 2015, 6:234-242.
78. Belcheva A., et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells. Cell 2014, 158:288-299.
79. Clarke J.M., et al. Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats. Carcinogenesis 2008, 29:2190-2194.
80. Spranger S., et al. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523:231-235.
81. Lu R., et al. Enteric bacterial protein AvrA promotes colonic tumorigenesis and activates colonic beta-catenin signaling pathway. Oncogenesis 2014, 3:e105.
82. Lu R., et al. Consistent activation of the beta-catenin pathway by Salmonella type-three secretion effector protein AvrA in chronically infected intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G1113-G1125.
83. Zaiss M.M., et al. The intestinal microbiota contributes to the ability of helminths to modulate allergic inflammation. Immunity 2015, 43:998-1010.
84. Imaoka A., et al. Proliferative recruitment of intestinal intraepithelial lymphocytes after microbial colonization of germ-free mice. Eur. J. Immunol. 1996, 26:945-948.
85. Yamanaka T., et al. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J. Immunol. 2003, 170:816-822.
86. + cell responses. J. Immunol. 2003, 170:2727-2733.